register

News & Trends - Medical Technology

MTAA outlines policy priorities in 2021-22 pre-budget submission

Health Industry Hub | February 15, 2021 |
[Total: 1    Average: 5/5]

MedTech News: Medical Technology Association of Australia (MTAA)’s policy priorities highlighted in the pre-budget submission ahead of the 2021 Budget seek to provide overall savings, redirect existing funds or foster growth in the Australian economy.

As a priority, MTAA calls on the Federal Government to work with all private health sector stakeholders to reform and restore the sustainability of private health in Australia.

According to the MTAA submission “If private health insurers are able to make internal cost savings, either through efficiencies, or reducing high management expenses, that are reflected in a decrease in premiums, this may reverse the flow of people, particularly the young, leaving private health insurance and thus stop the so-called “death spiral” currently facing the industry.

“Some private health insurers have been quick to point the finger at medical devices and the Prostheses List (PL), calling for the PL to be scrapped and replaced with an a DRG model that would restrict patient access and surgeon choice. Whilst there are some issues with the PL that are currently being addressed, to say that reform of the PL would alleviate private health insurer’s woes would be false. Devices, via the PL, make up less than 14% of Insurers Hospital costs and less than 10% of insurers total benefits. The MedTech industry, via our Strategic Agreement with the Hon. Greg Hunt MP, is already delivering $1.1 billion in savings. As such, the Government must look beyond changes to the Prostheses List to deliver sustainability for the private health system.

“The trend towards utilising private health insurance as an investment model is fundamentally at odds with its use as a the provider of finance for healthcare.”

MTAA recommends for the Government to refer to the measurers laid out in AlphaBeta report Keeping Premiums Low: Towards a sustainable private healthcare system and the AMA’s Prescription for Private Health Insurance to ensure Australian families are not over-paying for private health insurance and private health insurance can remain sustainable into the future.

As the extension of the above, the submission addresses the imminent prostheses list (PL) reforms. The two PL reform options put forward by the Department of Health as part of the consultation process have significant drawbacks and will have negative consequences on patient access and surgeon choice of innovative medical technology, in addition to making the private hospitals less viable and private insurance less attractive.

“MTAA strongly supports retaining the current PL. Few parts of the private health insurance system have been as successful in retaining wide choice with no out-of-pocket costs. However, MTAA is proposing a version of option 2 which retains the best features of the current PL but provides reforms necessary to ensure its viability and sustainability into the future.”

MTAA’s pre-budget submission also recommends that the Government continue to explore how further utilisation of medical technology can improve the efficiencies of telehealth, and to include traditional and innovative telehealth solutions for a comprehensive and sustainable digital health platform in the future.

The submission extends on this digitisation focus by recommending that the $12 million over four years allocated to TGA’s Digital Transformation be brought forward in light of the European Union Medical Device Regulation (EU-MDR) changes and in addition to decreasing the regulatory burden and improving timely patient access to assessed technologies.

The importance of home grown medical technology research and development (R&D) was also addressed in this submission. The MTAA notes that for the past decade, gross R&D investment in Australia has declined, now currently at 1.88%, below the OECD average of 2.38%. Despite this, Australia has a history of supporting early-stage R&D which does not lead to its translation to commercialisation and export.

“Commercial growth is stalled as the process to translate research into commercialisation is not incentivised. Currently, there are no incentives for onshore commercialisation of IP, and results, in effect, to the exportation of government-funded IP at the precise time where there is opportunity for profitability, which would deliver further value to the Australian economy.”

MTAA welcomes further discussion with the Government on this point.

The full MTAA Pre-Budget Submission FY2021/22 can be accessed here.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Digital & Innovation

Healthcare Technology Digital Innovations - Shifts in Pharma’s digital health landscape - Deep dive with Dr Ramin Rafiei

Shifts in Pharma’s digital health landscape – Deep dive with Dr Ramin Rafiei

Health Industry Hub | March 1, 2021 |

In this Health Industry Hub interview, Dr Ramin Rafiei takes us on a deep dive into the current digital health […]

More


News & Trends - Pharmaceuticals

Pharma News - Boehringer Ingelheim reduces carbon footprint with launch of reusable inhaler

Boehringer Ingelheim reduces carbon footprint with launch of reusable inhaler

Health Industry Hub | March 1, 2021 |

Pharma News: Boehringer Ingelheim has reinforced its commitment to increased sustainability within the healthcare sector, launching a more eco-friendly version […]

More


Medical

$1.3 billion manufacturing funding opens for medicines and medical devices

Health Industry Hub | March 1, 2021 |

Medical News: The Morrison Government is backing Australia’s medical products manufacturers to grow and create new jobs, with applications for […]

More


News & Trends - Medical Technology

MedTech News - $100 million funding for major advances in medical technology

$100 million funding for major advances in medical technology

Health Industry Hub | March 1, 2021 |

MedTech News: $100 million is being invested into the development of new medical technologies to improve diagnosis and treatment of […]

More